Atyr PHARMA (NASDAQ:ATYR) Receives Buy Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Atyr PHARMA (NASDAQ:ATYR) in a report published on Monday morning,Benzinga reports. They currently have a $35.00 price target on the stock.

Other analysts have also issued research reports about the company. Leerink Partnrs raised Atyr PHARMA to a “strong-buy” rating in a research note on Tuesday, February 18th. Leerink Partners began coverage on Atyr PHARMA in a research note on Tuesday, February 18th. They issued an “outperform” rating and a $16.00 price target on the stock. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Atyr PHARMA presently has a consensus rating of “Buy” and a consensus target price of $18.60.

Atyr PHARMA Stock Performance

Shares of NASDAQ ATYR opened at $3.44 on Monday. The company has a market cap of $306.17 million, a P/E ratio of -3.66 and a beta of 0.79. The company has a quick ratio of 5.41, a current ratio of 5.41 and a debt-to-equity ratio of 0.02. Atyr PHARMA has a 12 month low of $1.42 and a 12 month high of $4.66. The business’s 50 day moving average is $3.26 and its two-hundred day moving average is $3.41.

Atyr PHARMA (NASDAQ:ATYR) last released its quarterly earnings data on Wednesday, May 7th. The company reported ($0.17) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.02. On average, equities analysts expect that Atyr PHARMA will post -0.91 EPS for the current year.

Hedge Funds Weigh In On Atyr PHARMA

A number of institutional investors and hedge funds have recently bought and sold shares of ATYR. Group One Trading LLC bought a new stake in shares of Atyr PHARMA during the fourth quarter worth $26,000. XTX Topco Ltd raised its position in shares of Atyr PHARMA by 74.9% during the first quarter. XTX Topco Ltd now owns 19,556 shares of the company’s stock worth $59,000 after acquiring an additional 8,374 shares during the last quarter. Alterna Wealth Management Inc. bought a new stake in shares of Atyr PHARMA during the fourth quarter worth $36,000. OMERS ADMINISTRATION Corp raised its position in shares of Atyr PHARMA by 7.3% during the first quarter. OMERS ADMINISTRATION Corp now owns 148,100 shares of the company’s stock worth $447,000 after acquiring an additional 10,100 shares during the last quarter. Finally, Victory Capital Management Inc. bought a new stake in Atyr PHARMA in the fourth quarter valued at about $37,000. Institutional investors and hedge funds own 61.72% of the company’s stock.

Atyr PHARMA Company Profile

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.